Safety of long-acting beta-agonists: urgent need to clear the air remains.
Beasley
R
R
Martinez
F D
FD
Hackshaw
A
A
Rabe
K F
KF
Sterk
P J
PJ
Djukanovic
R
R
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality*; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects*; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate